However, analysis of clinical trial data has revealed that multiple myeloma patients with low RPL5 mRNA expression levels respond better to the proteasome inhibitor bortezomib by comparison with patients with high RPL5 expression,203 highlighting the link described above between RP mutations and altered proteasomal activity. This evidence concerns the gene RPL5 and AL amyloidosis.